1. Al-Dabbagh, S.A., Idle, J.R. and Smith, R.L. (1981). Animal modelling of human polymorphic drug oxidation -the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol. 33: 161–164.
2. Anders, H.H. and Weber W.W. (1986). N-Acetylation pharmacogenetics: Michaelis Menten constants for arylamine drugs as predictors of their N-acetylation rates in vivo. Drug Metab. Dispos. 14: 382–385.
3. Barbeau, A., Cloutier, T., Roy M., Plasse, L., Paris, S. and Poirier, J. (1985). Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet ii: 1213–1215.
4. Barbeau, A., Roy, M., Cloutier, T., Plasse, L. and Paris, S. (1986). Environmental and genetic factors in the etiology of Parkinson’s disease. Adv. Neurol. 45: 299–306.
5. Biehl, J.P. (1957). Emergence of drug resistance as related to the dosage and metabolism of isoniazid. Trans 16th Conf Chemother Tuberc Washington D.C. US Veterans Adm. Army Navy, 108–113.